Alignment Healthcare’s first quarter results for 2025 were marked by strong revenue and non-GAAP profit that both exceeded Wall Street expectations, but the market responded with a notable decline in the stock price. Management attributed the robust performance to 32% year-over-year membership growth and steady execution of its care management model, particularly in both California and its newer markets. CEO John Kao emphasized progress in scaling the clinical platform and outperforming on key inpatient utilization metrics, stating that “our business model is Medicare Advantage done right.” Additionally, lower administrative expenses and improved gross profit margins reflected operational efficiencies as the company expanded its member base.
Is now the time to buy ALHC? Find out in our full research report (it’s free).
Alignment Healthcare (ALHC) Q1 CY2025 Highlights:
- Revenue: $926.9 million vs analyst estimates of $888.1 million (47.5% year-on-year growth, 4.4% beat)
- Adjusted EPS: $0.04 vs analyst estimates of -$0.07 (significant beat)
- Adjusted EBITDA: $20.18 million vs analyst estimates of $4.4 million (2.2% margin, significant beat)
- The company lifted its revenue guidance for the full year to $3.79 billion at the midpoint from $3.75 billion, a 1.2% increase
- EBITDA guidance for the full year is $49 million at the midpoint, above analyst estimates of $47.1 million
- Operating Margin: -0.6%, up from -6.5% in the same quarter last year
- Customers: 217,500, up from 189,100 in the previous quarter
- Market Capitalization: $2.71 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Alignment Healthcare’s Q1 Earnings Call
- Ryan Daniels (William Blair): Asked whether Alignment would pursue new strategic partnerships or expand its tech platform for provider enablement. CEO John Kao explained the company’s disciplined approach, emphasizing a focus on proven care models and careful assessment of expansion opportunities.
- Michael Ha (Baird): Inquired about the drivers of medical loss ratio (MLR) outperformance, specifically regarding Part D seasonality. CFO Thomas Freeman clarified that early Part D favorability was modest and not a major contributor, with overall utilization trends in line with expectations.
- Jessica Tassan (Piper Sandler): Sought insight into the competitive outlook in California and potential changes in capitated provider contracts. CEO John Kao and Freeman described Alignment’s differentiated contracting approach, limiting provider risk on supplemental benefits and emphasizing long-term alignment with partners.
- Joanna Gajuk (Bank of America): Questioned the impact of future reimbursement rate changes and risk adjustment model updates from CMS. CEO John Kao highlighted Alignment’s adaptability to both rising and compressed rates, citing operational efficiency as a key advantage.
- Matthew Gillmor (KeyBanc): Asked for details on utilization trends and how membership mix affects inpatient admissions. Freeman confirmed that, when normalized for member mix, inpatient utilization was flat, and other cost categories remained stable or below expectations.
Catalysts in Upcoming Quarters
In the upcoming quarters, the StockStory team will be monitoring (1) the pace of membership growth in both core and expansion markets, (2) the sustainability of medical cost management amid changing pharmacy utilization and regulatory shifts, and (3) the effectiveness of the new CFO transition in supporting operational scale. Additionally, ongoing updates to the AVA technology platform and execution of new provider partnerships will serve as important indicators of future performance.
Alignment Healthcare currently trades at $13.70, down from $16.71 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.